Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
First Claim
Patent Images
1. A method of inhibiting cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising administering to a patient a compound of the formula:
- ##STR89## wherein Ar is selected from substituted or unsubstituted phenyl, α
-naphthyl, β
-naphthyl, indazolyl, indanyl, pyrazolyl, pyridinyl, indol-3-yl, benzodioxan-6-yl, 1,2,3,4-tetrahydroquinolin-1-yl, or 2,3-dihydroindol-1-yl where the substituents may be located at any appropriate position of the ring system and are described by R;
X is a bond, O, S, NHCH2 or NR4 ;
R independently includes hydrogen, alkyl, hydroxy, alkoxy, phenyl, aralkyl, alkylsulphonyl, haloalkyl or halo;
R5 is hydrogen or alkoxy;
R6 and R7 are alkoxy; and
R4 is hydrogen, methyl, ethyl or benzyl;
or a pharmaceutically acceptable salt thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compounds and their use in pharmaceutical compositions is described.
331 Citations
14 Claims
-
1. A method of inhibiting cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising administering to a patient a compound of the formula:
- ##STR89## wherein Ar is selected from substituted or unsubstituted phenyl, α
-naphthyl, β
-naphthyl, indazolyl, indanyl, pyrazolyl, pyridinyl, indol-3-yl, benzodioxan-6-yl, 1,2,3,4-tetrahydroquinolin-1-yl, or 2,3-dihydroindol-1-yl where the substituents may be located at any appropriate position of the ring system and are described by R;X is a bond, O, S, NHCH2 or NR4 ; R independently includes hydrogen, alkyl, hydroxy, alkoxy, phenyl, aralkyl, alkylsulphonyl, haloalkyl or halo; R5 is hydrogen or alkoxy; R6 and R7 are alkoxy; and R4 is hydrogen, methyl, ethyl or benzyl;
or a pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6)
- ##STR89## wherein Ar is selected from substituted or unsubstituted phenyl, α
-
7. A compound selected from the group consisting of:
-
4-(3,4,5-trimethoxyphenylamino)-6,7-dimethoxyquinazoline, 4-(N-methyl-3,4,5-trimethoxyanilino)-6,7-dimethoxyquinazoline, 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline, 4-(N-methyl-4-chloroanilino)-6,7-dimethoxyquinazoline, (6,7-dimethoxyquinazolin-4-yl)methyl-(3-trifluoromethylphenyl)amine, (3-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)methylamine, N-phenyl-N-(6,7,8-dimethoxyquinazolin-4-yl)methylamine, (3-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)ethylamine, (6,7-dimethoxyquinazolin-4-yl)methyl-p-tolyl-amine, (4-methoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine, (3,5-dimethoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine, and 6,7-dimethoxy-4-(N-methylanilino)quinazoline;
or a pharmaceutically acceptable salt thereof.
-
-
8. A compound which is 4-(pyrazol-3-ylamino)-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.
-
9. A compound selected from the group consisting of:
-
(6,7-dimethoxyquinazolin-4-yl)-5-indazolylamine, 4- N-(5-indanyl)amino!-6,7-dimethoxyquinazoline, 4-(3,6-dioxananilino)-6,7-dimethoxyquinazoline, 6,7-dimethoxy-4-(α
-naphthylamino)quinazoline, and6,7-dimethoxy-4-(β
-naphthylamino)quinazoline;
or a pharmaceutically acceptable salt thereof. - View Dependent Claims (12)
-
-
10. A compound selected from the group consisting of:
-
4-(3,4,5-trimethoxyphenoxy)-6,7-dimethoxyquinazoline, 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline, 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, and 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline;
or a pharmaceutically acceptable salt thereof.
-
-
11. A compound selected from the group consisting of:
-
4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline, 4-(naphthalen-1-yl)-6,7-dimethoxyquinazoline, 4-(naphthalen-2-yl)-6,7-dimethoxyquinazoline, 4-(3-fluoro-4-methoxyphenyl)-6,7-dimethoxyquinazoline, 4-(3-phenylphenyl)-6,7-dimethoxyquinazoline, 4-(2-methoxypyridin-5-yl)-6,7-dimethoxyquinazoline, 4-(1-benzylindol-3-yl)-6,7-dimethoxyquinazoline, 4-(indol-3-yl)-6,7-dimethoxyquinazoline, 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline, 4-(1-methylsulphonylindol-3-yl)-6,7-dimethoxyquinazoline, (±
)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline,4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline, and 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline;
or a pharmaceutically acceptable salt thereof. - View Dependent Claims (13, 14)
-
Specification